Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

about

Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Item

http://www.wikidata.org/entity/Q47206128

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pegylated Liposomal Irinotecan ...... E Single Technology Appraisal.

@en

Pegylated Liposomal Irinotecan ...... E Single Technology Appraisal.

@nl

type

Item

label

Pegylated Liposomal Irinotecan ...... E Single Technology Appraisal.

@en

Pegylated Liposomal Irinotecan ...... E Single Technology Appraisal.

@nl

prefLabel

Pegylated Liposomal Irinotecan ...... E Single Technology Appraisal.

@en

Pegylated Liposomal Irinotecan ...... E Single Technology Appraisal.

@nl

P1476

Pegylated Liposomal Irinotecan ...... E Single Technology Appraisal.

@en

P2093

Adrian Bagust

http://www.w3.org/2001/XMLSchema#string

Ahmed Abdulla

http://www.w3.org/2001/XMLSchema#string

Angela Boland

http://www.w3.org/2001/XMLSchema#string

Angela Stainthorpe

http://www.w3.org/2001/XMLSchema#string

Daniel Palmer

http://www.w3.org/2001/XMLSchema#string

Eleanor Kotas

http://www.w3.org/2001/XMLSchema#string

Joanne McEntee

http://www.w3.org/2001/XMLSchema#string

Nigel Fleeman

http://www.w3.org/2001/XMLSchema#string

Sophie Beale

http://www.w3.org/2001/XMLSchema#string

P2860

The average body surface area of adult cancer patients in the UK: a multicentre retrospective study

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK01

Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.

P2888

s40273-017-0592-3

P304

289-299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-017-0592-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marty Richardson

P577

2017-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29178025

http://www.w3.org/2001/XMLSchema#string